Abstrakt

Przypisy

• 1. Ariyoshi H., Okuyama M., Okahara K., Kawasaki T., KambayashiJ., Sakon M., Monden M.: Expanded polytetrafluoroethylene (ePTFE)vascular graft loses its thrombogenicity six months after implantation.Thromb. Res., 1997; 88: 427-433
  Google Scholar
• 2. Blann A.D.: Plasma von Willebrand factor, thrombosis, and theendothelium: the first 30 years. Thromb. Haemost., 2006; 95: 49-55
  Google Scholar
• 3. Blann A.D., Naqvi T., Waite M., McCollum C.N.: von Willebrandfactor and endothelial damage in essential hypertension. J. Hum.Hypertens., 1993; 7: 107-111
  Google Scholar
• 4. Bongers T.N., de Maat M.P., van Goor M.L., Bhagwanbali V., vanVliet H.H., Gómez García E.B., Dippel D.W., Leebeek F.W.: High vonWillebrand factor levels increase the risk of first ischemic stroke:influence of ADAMTS13, inflammation, and genetic variability. Stroke,2006; 37: 2672-2677
  Google Scholar
• 5. Gabrusiewicz A., Słowiński P., Krosny T., Staszkiewicz W.: Thepresent state of the art of the pathophysiology, diagnosis and treatmentof the superficial femoral artery occlusion based on ownresults. Postępy N. Med., 2012; 25: 612-616
  Google Scholar
• 6. Goodney P.P., Beck A.W., Nagle J., Welch H.G., Zwolak R.M.: Nationaltrends in lower extremity bypass surgery, endovascular interventions,and major amputations. J. Vasc. Surg., 2009; 50: 54-60
  Google Scholar
• 7. Grinnel B.W., Berg D.T.: Surface thrombomodulin modulatestrombin receptor responses on vascular smooth muscle cells. Am.J. Physiol., 1996; 270: H603-H609
  Google Scholar
• 8. Hoshiba Y., Hatakeyama K., Tanabe T., Asada Y., Goto S.: Co-localizationof von Willebrand factor with platelet thrombi, tissue factor andplatelets with fibrin, and consistent presence of inflammatory cells incoronary thrombi obtained by an aspiration device from patients withacute myocardial infarction. J. Thromb. Haemost., 2006; 4: 114-120
  Google Scholar
• 9. Juni R.P., Duckers H.J., Vanhoutte P.M., Virmani R., Moens A.L.:Oxidative stress and pathological changes after coronary artery interventions.J. Am. Coll. Cardiol., 2013, 9; 61: 1471-1481
  Google Scholar
• 10. Kotschy M., Kotschy D., Witkiewicz W.: Rola czynnika tkankowegoi jego inhibitora w procesie krzepnięcia krwi oraz w powikłaniachzakrzepowych. Kardiol. Pol., 2010; 68: 1158-1162
  Google Scholar
• 11. Leurs P.B., Stolk R.P., Hamulyak K., Van Oerle R., Grobbee D.E.,Wolffenbuttel B.H.: Tissue factor pathway inhibitor and other endothelium-dependenthemostatic factors in elderly individuals withnormal or impaired glucose tolerance and type 2 diabetes. DiabetesCare, 2002; 25: 1340-1345
  Google Scholar
• 12. Li J.M., Singh M.J., Itani M., Vasiliu C., Hendricks G., Baker S.P.,Hale J.E., Rohrer M.J., Cutler B.S., Nelson P.R.: Recombinant humanthrombomodulin inhibits arterial neointimal hyperplasia after ballooninjury. J. Vasc. Surg., 2004; 39: 1074-1083
  Google Scholar
• 13. Lwaleed B.A., Bass P.S.: Tissue factor pathway inhibitor: structure,biology and involvement in disease. J. Pathol., 2006; 208: 327-339
  Google Scholar
• 14. Makin A., Silverman S.H., Lip G.Y.: Peripheral vascular diseaseand Virchow’s triad for thrombogenesis. QJM, 2002; 95: 199-210
  Google Scholar
• 15. Migdalski A., Jawien A., Kotschy M., Knapik-Bieniek A.: Selectedhaemostatic factors in carotid bifurcation plaques of patientsundergoing carotid endarterectomy. Eur. J. Vasc. Endovasc. Surg.,2004, 27: 172-179
  Google Scholar
• 16. Migdalski A., Kotschy M., Jawien A.: Tissue factor, tissue factorpathway inhibitor and vascular endothelial growth factor-A incarotid atherosclerotic plaques. Eur. J. Vasc. Endovasc. Surg., 2005;30: 41-47
  Google Scholar
• 17. Mizuno O., Ikeda U., Hojo Y., Fujikawa H., Katsuki T., ShimadaK.: Tissue factor expression in coronary circulation as a prognosticfactor for late restenosis after coronary angioplasty. Cardiology,2001; 95: 84-89
  Google Scholar
• 18. Monaco M., Di Tommaso L., Stassano P., Smimmo R., De AmicisV., Pantaleo A., Pinna G.B., Iannelli G.: Impact of blood coagulationand fibrinolytic system changes on early and mid term clinical outcomein patients undergoing stent endografting surgery. Interact.Cardiovasc. Thorac. Surg., 2006, 5: 724-728
  Google Scholar
• 19. Pärsson H., Holmberg A., Siegbahn A., Bergqvist D.: Activationof coagulation and fibrinolytic systems in patients with CLI is notnormalized after surgical revascularisation. Eur. J. Vasc. Endovasc.Surg., 2004; 27: 186-192
  Google Scholar
• 20. Paulinska P., Spiel A., Jilma B.: Role of von Willebrand factor invascular disease. Hamostaseologie, 2009; 29: 32-38
  Google Scholar
• 21. Radziwon P., Bielawiec M., Kłoczko J., Giedrojć J., MazgajskaK., Galar M.,Klimiuk M.: Tissue factor pathway inhibitor (TFPI) inpatients with occlusive arterial diseases in consideration with riskfactors and conservative treatment of the disease. Acta Angiol.,2001; 7: 43-54
  Google Scholar
• 22. Rowe V.L., Lee W., Weaver F.A., Etzioni D.: Patterns of treatmentfor peripheral arterial disease in the United States: 1996-2005. J.Vasc. Surg., 2009; 49: 910-917
  Google Scholar
• 23. Smith F.B., Lee A.J., Hau C.M., Rumley A., Lowe G.D., Fowkes F.G.:Plasma fibrinogen, haemostatic factors and prediction of peripheralarterial disease in the Edinburgh Artery Study. Blood Coagul. Fibrinolysis,2000; 11: 43-50
  Google Scholar
• 24. Speiser W., Speiser P., Minar E., Korninger C., Niessner H., HuberK., Schernthaner G., Ehringer H., Lechner K.: Activation of coagulationand fibrinolysis in patients with arteriosclerosis: relation tolocalization of vessel disease and risk factors. Thromb. Res., 1990;59: 77-88
  Google Scholar
• 25. Spiel A.D., Gilbert J.C., Jilma B.: Von Willebrand factor in cardiovasculardiseases: focus on acute coronary syndromes. Circulation,2008; 117: 1449-1459
  Google Scholar
• 26. Steffel J., Lüscher T.F., Tanner F.C.: Tissue factor in cardiovasculardiseases: molecular mechanisms and clinical implications.Circulation, 2006; 113: 722-731
  Google Scholar
• 27. Strano A., Hoppensteadt D., Walenga J.M., Fareed J., Sabbá C.,Berardi E., Allegra C., Carlizza A., Binaghi F., Fronteddu F., Del GuercioR., Del Guercio M., Pinto A., Alletto G., Nazzari M., Ferrari P.A.: Plasmalevels of the molecular markers of coagulation and fibrinolysis inpatients with peripheral arterial disease. Semin. Thromb. Hemost.,1996; 22 (Suppl. 1): 35-40
  Google Scholar
• 28. Tamburino C., Ussia G.P., Zimarino M., Galassi A.R., De CaterinaR.: Early restenosis after drug-eluting stent implantation: A putativerole for platelet activation. Can. J. Cardiol., 2007; 23: 57-59
  Google Scholar
• 29. Tsakiris D.A., Tschöpl M., Jäger K., Haefeli W.E., Wolf F., MarbetG.A.: Circulating cell adhesion molecules and endothelial markersbefore and after transluminal angioplasty in peripheral arterial occlusivedisease. Atherosclerosis, 1999; 142: 193-200
  Google Scholar
• 30. Tschopl M., Tsakiris D.A., Marbet G.A., Labs K.H., Jäger K.: Roleof hemostatic risk factors for restenosis in peripheral arterial occlusivedisease after transluminal angioplasty. Arterioscler. Thromb.Vasc. Biol., 1997; 17: 3208-3214
  Google Scholar
• 31. Wu K.K., Thiagarajan P.: Role of endothelium in thrombosis andhemostasis. Annu. Rev. Med., 1996; 47: 315-331
  Google Scholar
• 32. Xia Z.Y., Yang H., Qu H.Q., Cheng W.D., Wang L.X.: Expressionof P-selectin, von Willebrand and endothelin-1 after carotid arterystenting. Vasa, 2011; 40: 199-204
  Google Scholar

Pełna treść artykułu